+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Anticoagulants Market by Route of Administration, Anticoagulant Drug, Drug Class, Application - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 4904671
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Anticoagulants Market grew from USD 40.20 billion in 2023 to USD 44.24 billion in 2024. It is expected to continue growing at a CAGR of 10.14%, reaching USD 79.07 billion by 2030.

Anticoagulants, widely referred to as blood thinners, are medications that prevent blood coagulation, thereby reducing the risk of thrombosis (blood clots). The growing prevalence of cardiovascular diseases and the increasing incidence of venous thromboembolism, stroke, and other clot-related conditions mandate the necessity of anticoagulants in modern healthcare. They are extensively applied in clinical settings for both prophylactic and therapeutic purposes, employed predominantly in surgeries, chronic conditions like atrial fibrillation, and during recovery phases post-diagnosis of thrombotic events. The end-use scope primarily spans hospitals, clinics, and ambulatory surgical centers, with potential consumer usage in chronic disease management at home settings supported by the rise in e-pharmacies and telemedicine services. The anticoagulant market experiences significant influence from factors such as the expanding geriatric population susceptible to clot-related disorders and advancements in drug delivery systems improving patient compliance and outcomes. Nonetheless, market growth is challenged by limitations such as high treatment costs, risks of bleeding associated with anticoagulant therapy, and stringent regulatory frameworks. Opportunities exist in emerging markets owing to the increasing healthcare expenditure and awareness programs on cardiovascular health. Strategic partnerships and R&D in developing novel anticoagulants with reduced side effects and expanded indications could harness market potential. Moreover, personalized medicine can cater to individual patient profiles, ensuring optimal therapeutic benefits. However, the market also faces competition from alternative therapies and biosimilars emergence. The innovation frontier lies in developing safer, more convenient anticoagulant options, possibly through oral or transdermal delivery systems, reducing patient burden. The nature of the anticoagulant market is dynamic, with an inclination towards personalized and precision medicine, guided by technological advancements and a deeper understanding of clotting mechanisms, ensuring broader access and improved patient outcomes.

Understanding Market Dynamics in the Anticoagulants Market

The Anticoagulants Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of venous thromboembolism and cardiovascular disorders
    • Rising number of anticoagulation stewardship programs
    • Increasing acceptance of novel oral anticoagulants
  • Market Restraints
    • Stringent regulations related to drug dosage and clinical approvals
  • Market Opportunities
    • Introduction of novel anticoagulation therapeutics and increasing R&D investments
    • Use of AI and ML to predict anticoagulation control
  • Market Challenges
    • Side-effects and complications associated with the usage of oral anticoagulants

Exploring Porter’s Five Forces for the Anticoagulants Market

Porter’s Five Forces framework further strengthens the insights of the Anticoagulants Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Anticoagulants Market

External macro-environmental factors deeply influence the performance of the Anticoagulants Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Anticoagulants Market

The Anticoagulants Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Anticoagulants Market

The Anticoagulants Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Anticoagulants Market

The Anticoagulants Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anticoagulants Market, highlighting leading vendors and their innovative profiles. These include Akebia Therapeutics, Inc., Aspen Pharmacare Holdings Limited, AstraZeneca PLC, Athenex, Inc., Bayer AG, C.H. Boehringer Sohn AG & Ko. KG, Eisai Co., Ltd., Eli Lilly and Company, Johnson & Johnson, LEO Pharma A/S, Novartis AG, Pfizer Inc., Sanofi S.A., Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Anticoagulants Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Route of Administration
    • Injectable Anticoagulants
    • Oral Anticoagulants
  • Anticoagulant Drug
    • Betrixaban
    • Dabigatran
    • Edoxaban or Rivaroxaban
    • Eliquis
  • Drug Class
    • DTIs
    • Factor XA Inhibitors
    • Heparin
    • Vitamin K Antagonists
  • Application
    • Atrial fibrillation & Heart Attack
    • Deep Vein Thrombosis
    • Pulmonary Embolism
    • Stroke
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of venous thromboembolism and cardiovascular disorders
5.1.1.2. Rising number of anticoagulation stewardship programs
5.1.1.3. Increasing acceptance of novel oral anticoagulants
5.1.2. Restraints
5.1.2.1. Stringent regulations related to drug dosage and clinical approvals
5.1.3. Opportunities
5.1.3.1. Introduction of novel anticoagulation therapeutics and increasing R&D investments
5.1.3.2. Use of AI and ML to predict anticoagulation control
5.1.4. Challenges
5.1.4.1. Side-effects and complications associated with the usage of oral anticoagulants
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Anticoagulants Market, by Route of Administration
6.1. Introduction
6.2. Injectable Anticoagulants
6.3. Oral Anticoagulants
7. Anticoagulants Market, by Anticoagulant Drug
7.1. Introduction
7.2. Betrixaban
7.3. Dabigatran
7.4. Edoxaban or Rivaroxaban
7.5. Eliquis
8. Anticoagulants Market, by Drug Class
8.1. Introduction
8.2. DTIs
8.3. Factor XA Inhibitors
8.4. Heparin
8.5. Vitamin K Antagonists
9. Anticoagulants Market, by Application
9.1. Introduction
9.2. Atrial fibrillation & Heart Attack
9.3. Deep Vein Thrombosis
9.4. Pulmonary Embolism
9.5. Stroke
10. Americas Anticoagulants Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Anticoagulants Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Anticoagulants Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ANTICOAGULANTS MARKET RESEARCH PROCESS
FIGURE 2. ANTICOAGULANTS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTICOAGULANTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ANTICOAGULANTS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. ANTICOAGULANTS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANTICOAGULANTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTICOAGULANTS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANTICOAGULANTS MARKET DYNAMICS
TABLE 7. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INJECTABLE ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ORAL ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTICOAGULANTS MARKET SIZE, BY BETRIXABAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DABIGATRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTICOAGULANTS MARKET SIZE, BY EDOXABAN OR RIVAROXABAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ELIQUIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DTIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTICOAGULANTS MARKET SIZE, BY HEPARIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ATRIAL FIBRILLATION & HEART ATTACK, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTICOAGULANTS MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTICOAGULANTS MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 38. CANADA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. CANADA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 40. CANADA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. CANADA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. MEXICO ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. MEXICO ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 44. MEXICO ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. MEXICO ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 58. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. CHINA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. CHINA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 62. CHINA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. CHINA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. INDIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. INDIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 66. INDIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. INDIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 70. INDONESIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. INDONESIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 72. JAPAN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. JAPAN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 74. JAPAN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. JAPAN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 78. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 82. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 86. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 90. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 94. TAIWAN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. TAIWAN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. THAILAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. THAILAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 98. THAILAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. THAILAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 102. VIETNAM ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. VIETNAM ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 109. DENMARK ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. DENMARK ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 111. DENMARK ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. DENMARK ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. EGYPT ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. EGYPT ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 115. EGYPT ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. EGYPT ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. FINLAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. FINLAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 119. FINLAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. FINLAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. FRANCE ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. FRANCE ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 123. FRANCE ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. FRANCE ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. GERMANY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. GERMANY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 127. GERMANY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. GERMANY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 131. ISRAEL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 132. ISRAEL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. ITALY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. ITALY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 135. ITALY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. ITALY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 143. NIGERIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. NIGERIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. NORWAY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. NORWAY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 147. NORWAY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. NORWAY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. POLAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. POLAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 151. POLAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 152. POLAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. QATAR ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. QATAR ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 155. QATAR ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. QATAR ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. SPAIN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. SPAIN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 171. SPAIN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 172. SPAIN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 179. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. TURKEY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. TURKEY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 183. TURKEY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. TURKEY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. ANTICOAGULANTS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 194. ANTICOAGULANTS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Anticoagulants Market, which are profiled in this report, include:
  • Akebia Therapeutics, Inc.
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca PLC
  • Athenex, Inc.
  • Bayer AG
  • C.H. Boehringer Sohn AG & Ko. KG
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Johnson & Johnson
  • LEO Pharma A/S
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information